HS-10501 / Jiangsu Hansoh Pharma - LARVOL DELTA

Hansoh Pharmaceuticals HS-10501 tablets start Phase I clinical trial for overweight and obese adults [Google translation] (Sina Corp) - "Data from the Drug Clinical Trial Registration and Information Disclosure Platform show that Jiangsu Hausen Pharmaceutical Group Co., Ltd...has started a study to evaluate the effect of HS-10501 tablets on the pharmacokinetics of metformin hydrochloride tablets and rosuvastatin calcium tablets in healthy participants. The clinical trial registration number is CTR20252588, and the first public information date is July 2, 2025...The primary endpoint indicators of this trial include the main PK parameters (Cmax, AUC0-t, AUC0-∞) of metformin and rosuvastatin after metformin hydrochloride tablets and rosuvastatin calcium tablets are used alone or in combination with HS-10501 tablets; secondary endpoint indicators include other PK parameters of metformin and rosuvastatin, PK parameters of HS-10501, and safety indicators (adverse events, vital signs, etc.)....Currently, the experiment is in progress (not yet recruited), with a target enrollment of 12 people."

Trial status • Obesity

A Study of HS-10501 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

New P1 trial